Neumedicines Inc., a privately held company developing therapies based on interleukin 12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT), today announced that data from a study investigating the mechanism of action of HemaMax™ (recombinant human interleukin-12 or rHuIL-12) in healthy human subjects was presented at the 55th Annual American Society of Hematology (ASH) conference held in New Orleans from December 7-10, 2013.
Help employers find you! Check out all the jobs and post your resume.
